Cite

    Ioana Agache et al.. “Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma.” Allergy, vol. 75, no. 5, 2020, pp. 1023–1042. http://access.bl.uk/ark:/81055/vdc_100103795644.0x00003f